Tonix: FDA Will Not Require AdCom Meeting on Fibromyalgia Med

 On track for August 15, 2025 FDA PDUFA goal date

TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years

Commercial planning for TNX-102 SL underway for launch in the fourth quarter of 2025

https://www.globenewswire.com/news-release/2025/03/24/3047773/28908/en/Tonix-Pharmaceuticals-Announces-that-FDA-Will-Not-Require-an-Advisory-Committee-Meeting-to-Discuss-New-Drug-Application-for-TNX-102-SL-for-the-Management-of-Fibromyalgia.html